BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cho ME, Hansen JL, Peters CB, Cheung AK, Greene T, Sauer BC. An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease. Kidney International 2019;96:750-60. [DOI: 10.1016/j.kint.2019.04.029] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Babitt JL, Eisenga MF, Haase VH, Kshirsagar AV, Levin A, Locatelli F, Małyszko J, Swinkels DW, Tarng DC, Cheung M, Jadoul M, Winkelmayer WC, Drüeke TB; Conference Participants. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int 2021;99:1280-95. [PMID: 33839163 DOI: 10.1016/j.kint.2021.03.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wojtaszek E, Glogowski T, Malyszko J. Iron and Chronic Kidney Disease: Still a Challenge. Front Med (Lausanne) 2020;7:565135. [PMID: 33392212 DOI: 10.3389/fmed.2020.565135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Besarab A, Drueke TB. The problem with transferrin saturation as an indicator of iron 'sufficiency' in chronic kidney disease. Nephrol Dial Transplant 2021;36:1377-83. [PMID: 32301986 DOI: 10.1093/ndt/gfaa048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Honda H, Kimachi M, Kurita N, Joki N, Nangaku M. Low rather than high mean corpuscular volume is associated with mortality in Japanese patients under hemodialysis. Sci Rep 2020;10:15663. [PMID: 32973294 DOI: 10.1038/s41598-020-72765-2] [Reference Citation Analysis]
5 Del Vecchio L, Ekart R, Ferro CJ, Malyszko J, Mark PB, Ortiz A, Sarafidis P, Valdivielso JM, Mallamaci F; ERA-EDTA European Renal and Cardiovascular Medicine Working (EURECA-m) Group. Intravenous iron therapy and the cardiovascular system: risks and benefits. Clin Kidney J 2021;14:1067-76. [PMID: 34188903 DOI: 10.1093/ckj/sfaa212] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Guedes M, Muenz DG, Zee J, Bieber B, Stengel B, Massy ZA, Mansencal N, Wong MMY, Charytan DM, Reichel H, Waechter S, Pisoni RL, Robinson BM, Pecoits-Filho R; CKDopps Investigators. Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia. J Am Soc Nephrol 2021;32:2020-30. [PMID: 34244326 DOI: 10.1681/ASN.2020101531] [Reference Citation Analysis]
7 Xu Y, Alfaro-Magallanes VM, Babitt JL. Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders. Br J Haematol 2021;193:882-93. [PMID: 33316086 DOI: 10.1111/bjh.17252] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Zhao L, Zou Y, Zhang J, Zhang R, Ren H, Li L, Guo R, Zhang J, Liu F. Serum transferrin predicts end-stage Renal Disease in Type 2 Diabetes Mellitus patients. Int J Med Sci 2020;17:2113-24. [PMID: 32922172 DOI: 10.7150/ijms.46259] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Portolés J, Martín L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med (Lausanne) 2021;8:642296. [PMID: 33842503 DOI: 10.3389/fmed.2021.642296] [Reference Citation Analysis]
10 Wish JB, Anker SD, Butler J, Cases A, Stack AG, Macdougall IC. Iron Deficiency in CKD Without Concomitant Anemia. Kidney Int Rep 2021;6:2752-62. [PMID: 34805628 DOI: 10.1016/j.ekir.2021.07.032] [Reference Citation Analysis]
11 Diao X, Zheng Z, Yi C, Cao P, Ye H, Liu R, Lin J, Chen W, Mao H, Huang F, Yang X. Association of Abnormal Iron Status with the Occurrence and Prognosis of Peritoneal Dialysis-Related Peritonitis: A Longitudinal Data-Based 10-Year Retrospective Study. Nutrients 2022;14:1613. [DOI: 10.3390/nu14081613] [Reference Citation Analysis]
12 Guedes M, Muenz D, Zee J, Lopes MB, Waechter S, Stengel B, Massy ZA, Speyer E, Ayav C, Finkelstein F, Sesso R, Pisoni RL, Robinson BM, Pecoits-Filho R. Serum biomarkers of iron stores are associated with worse physical health-related quality of life (HRQoL) in non-dialysis dependent chronic kidney disease (NDD-CKD) patients with or without anemia. Nephrol Dial Transplant 2021:gfab050. [PMID: 33624825 DOI: 10.1093/ndt/gfab050] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Mehta R, Cho ME, Cai X, Lee J, Chen J, He J, Flack J, Shafi T, Saraf SL, David V, Feldman HI, Isakova T, Wolf M; CRIC Study Investigators. Iron status, fibroblast growth factor 23 and cardiovascular and kidney outcomes in chronic kidney disease. Kidney Int 2021:S0085-2538(21)00731-6. [PMID: 34339746 DOI: 10.1016/j.kint.2021.07.013] [Reference Citation Analysis]
14 Luo D, Zhong Z, Qiu Y, Wang Y, Li H, Lin J, Chen W, Yang X, Mao H. Abnormal iron status is associated with an increased risk of mortality in patients on peritoneal dialysis. Nutr Metab Cardiovasc Dis 2021;31:1148-55. [PMID: 33618923 DOI: 10.1016/j.numecd.2020.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Cases A, Puchades MJ, de Sequera P, Quiroga B, Martin-Rodriguez L, Gorriz JL, Portolés J; en representación del Grupode Anemia de la S.E.N. Iron replacement therapy in the management of anaemia in non-dialysis Chronic kidney disease patients: Perspective of the Spanish Nephrology Society Anaemia Group. Nefrologia 2021;41:123-36. [PMID: 34053886 DOI: 10.1016/j.nefroe.2020.11.011] [Reference Citation Analysis]